Results for pioglitazonbehandling translation from Danish to English

pioglitazonbehandling kan initieres med 15 mg eller 30 mg én gang dagligt.
pioglitazone treatment may be initiated at 15 mg or 30 mg once daily.

som supplement til pioglitazonbehandling (n=163) sitagliptin 100 mg én gang dagligt
sitagliptin 100 mg once daily added to -0.7‡ ongoing pioglitazone therapy (n=163) sitagliptin 100 mg once daily added to

i kombination med insulin kan den aktuelle insulindosis fortsættes, efter pioglitazonbehandling er påbegyndt.
in combination with insulin, the current insulin dose can be continued upon initiation of pioglitazone therapy.

fordelen ved at give trajenta sammen med pioglitazonbehandling blev dog ikke anset for at være blevet fastslået i tilstrækkeligt omfang.
however the benefit of adding trajenta to pioglitazone treatment was not considered to have been sufficiently established.

hvis alt-niveauer øges til 3 x den øvre normale grænse under pioglitazonbehandling, bør leverenzymniveauer vurderes igen så hurtigt som muligt.
if alt levels are increased to 3 x upper limit of normal during pioglitazone therapy, liver enzyme levels should be reassessed as soon as possible.

hvis alt- niveauer øges til 3 x den øvre normale grænse under pioglitazonbehandling, bør 14 leverenzymniveauer vurderes igen så hurtigt som muligt.
if alt

i kontrollerede kliniske forsøg er hyppigheden af rapporteret hjerteinsufficiens ved pioglitazonbehandling den samme som for placebo -, metformin - og sulfonylurinstof- grupperne.
in controlled clinical trials the incidence of reports of heart failure with pioglitazone treatment was the same as in placebo, metformin and sulphonylurea treatment groups.

3 i kontrollerede kliniske undersøgelser er hyppigheden af rapporteret hjerteinsufficiens ved pioglitazonbehandling den samme som for placebo-, metformin- og sulfonylurinstof-grupperne, men var forøget ved kombinationsbehandling med insulin.
3 in controlled clinical trials the incidence of reports of heart failure with pioglitazone treatment was the same as in placebo, metformin and sulphonylurea treatment groups, but was increased when used in combination therapy with insulin.